Our Story

In 2002, a successful Proof of Concept trial led by Pr Philippe HENON – Founder and Director of IRHT Mulhouse - showing structural and functional regeneration of myocardial tissue as well as reperfusion of an infarcted zone after a recent Acute Myocardial Infarct (AMI) was performed and included 7 myocardial infarction patients with a very poor short-term prognosis. Based on the objective of building a robust and automated bioprocessing technology aimed at producing a large amount of purified stem cells, CellProthera has developed a proprietary technology platform made of an automated expansion device StemXpand® and its disposable kit StemPack®. The final cell product ProtheraCytes® is made of CD34+ stem cells which have been confirmed to have potential for regeneration of various damaged tissues. ProtheraCytes® is registered as an ATMP – Advanced Therapy Medicinal Product – within the classification of Tissue Engineered product by the European Medicines Agency. Our most advanced program is the regeneration of damaged heart tissue after severe AMI to prevent Heart Failure (HF). It is an unmet medical need for a million patients per year only in the US, Europe and Japan.
Since this pilot study, CellProthera has a followup of more than 15 years. No other existing treatment whether it is stent, bypass or other drugs can show such results

Science & Technology

Adult stemcells are a natural resource available and capable of long-term self renewal. Our cellular product, ProtheraCytes® based on specific stemcells CD34+ together with our know how and technology is safe and has the power to regenerate multiple tissues

Therapy

Personnalized medicine for structural and functional regeneration of organs

News

Careers

The contribution of each employee is essential to the development and success of CellProthera